The case for reverse engineering ketamine and psychedelics: lessons from translational oncology. A Response to Miller et al. “Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies”-Reference-Cited by-同舟云学术

The case for reverse engineering ketamine and psychedelics: lessons from translational oncology. A Response to Miller et al. “Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies”

Published:2023-05-12 Issue:8 Volume:28 Page:3164-3166
ISSN:1359-4184
Container-title:Molecular Psychiatry
language:en
Short-container-title:Mol Psychiatry

Author:

Jones Gregory^ORCID,Machado-Vieira Rodrigo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology

Link

https://www.nature.com/articles/s41380-023-02102-2.pdf

Reference19 articles.

1. Miller AH, Raison CL. Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies. Mol Psychiatry. 2022 https://doi.org/10.1038/S41380-022-01887-Y.

2. Abhyankar D. Ipilimumab: a tale of twists and turns. South Asian J Cancer. 2018;7:193.

3. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–50.

4. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–86.

5. Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue‐agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharm Ther. 2021;109:334.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psychedelics and ketamine are a symptom of psychiatry’s woes, not a cure;Molecular Psychiatry;2023-06-23